Open AccessInhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin
Author(s) -
Brad Poore,
Ming Yuan,
Antje Arnold,
Antoinette Price,
Jesse Alt,
Jeffrey Rubens,
Barbara S. Slusher,
Charles G. Eberhart,
Eric H. Raabe
Publication year - 2018
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noy150
Subject(s) - carboplatin , everolimus , pi3k/akt/mtor pathway , cancer research , mtorc1 , in vivo , pharmacology , apoptosis , medicine , chemistry , biology , chemotherapy , oncology , cisplatin , biochemistry , microbiology and biotechnology
Pediatric low-grade glioma (pLGG) often initially responds to front-line therapies such as carboplatin, but more than 50% of treated tumors eventually progress and require additional therapy. With the discovery that pLGG often contains mammalian target of rapamycin (mTOR) activation, new treatment modalities and combinations are now possible for patients. The purpose of this study was to determine if carboplatin is synergistic with the mTOR complex 1 inhibitor everolimus in pLGG.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom